4D·

No further bid from

$NOVO B (-1,35%) . for the US biotech company Metsera.

In the billion-euro bidding war for the obesity specialist Metsera, the US pharmaceutical company $PFIZER against its Danish rival $NOVO B (-1,35%) Danish rival. In the expectation of a further booming market, Pfizer is taking over the previously loss-making US developer of weight loss drugs for around ten billion dollars, as both companies announced.

Novo Nordisk admitted defeat on Saturday and declared that it would not increase its now outbid offer any further.

Analysts criticized the price paid by $PFIZER the price paid as very high.

@Finanzkroko

16 Comentários

BamBamInvest@BamBamInvest

I even see this as positive, 10 billion would have been far too much and in the current situation such a high investment, even though the company only recently wanted to cut costs, also by laying off employees, would certainly have offended many. It will be interesting to see how the stock market reacts on Monday, but I think it will be positive. In my opinion, $PFE is shooting itself in the foot, as it remains to be seen what can really be generated with this takeover. Especially for a phase 2 product, which will probably not be ready for the market for another 2 years.

•

Michey777@Michey777

@BamBamInvest I also think that the stock market will react positively to $NOVO B. In any case, this is a negative point that the company is now losing. But the company's own pipeline still needs to be strengthened (in the long term).

•

BamBamInvest@BamBamInvest

@Michey777 Anyway, now I'm curious to see how the oral medication will develop. Let's hope there is no more bad news for the time being, then the share price will slowly rise again.

••

Michey777@Michey777

@BamBamInvest + the deal with Trump. FDA finally takes action against copy cats and fast-tracks approval prioritization. He's lining his own pockets again, but Americans will have to decide for themselves how they feel about that.

•

BamBamInvest@BamBamInvest

@Michey777 the deal with Trump will also have a positive effect in the end, the masses will also compensate for the cost reduction in the long term. I'm curious, but it will take time.

••

DasOnePiece@DasOnePiece

@BamBamInvest I can well understand the decision. In the current situation, such a huge expenditure would have been difficult to explain. It's probably better to be cautious for now.
Let's see how the stock market reacts. But I don't think it will be received negatively.

With Pfizer, I also wonder whether it's really worth it. The product is still a long way from being finished, a lot can still happen.

•

Solitair@Solitair

@BamBamInvest Stupid that I have both

•

Dividendenopi👴@Dividendenopi

@Solitair You are not alone 😅

•

BamBamInvest@BamBamInvest

@DasOnePiece We will probably only see that in the future, I haven't looked at the financial situation of $PFE, but it's probably not that easy to manage and apparently they must be pretty desperate. @Dividendenopi will probably have more insight, dividend in danger? What is the financial situation of $PFE?

•

BamBamInvest@BamBamInvest

@Solitair and are you still keeping both? 😊

••

BamBamInvest@BamBamInvest

@Dividendenopi well, I'm curious, that shouldn't be so easy for $PFE either, I assume.

••

Ver todas as 4 restantes respostas

Finanzaristokrat@Finanzaristokrat

Good decision by the CEO not to continue bidding.

•